FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306
Titel:
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306
Auteur:
Stintzing, S. Fischer von Weikersthal, L. Decker, T. Vehling-Kaiser, U. Jäger, E. Heintges, T. Stoll, C. Giessen, C. Modest, D.P. Neumann, J. Jung, A. Kirchner, T. Scheithauer, W. Heinemann, V.